In breast carcinoma, targeted therapy against HER2 using the humanized monoclonal antibody trastuzumab has now become integrated into standard adjuvant treatment regimens and has led to significant improvements in disease-free and overall survival in patients with Her2-positive cancer [3]. Here, ERBB2 is linked to breast carcinoma.